EISAI CO LTD (EII MU) stock market data APIs
€24.6434
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.MU.
Prev. Close
24.6434
Open
24.6434
High
24.6434
Low
24.6434
52 wk Range
21.5917-31.4821
Market Cap
15 022 M
EPS
39.18
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 32.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
Eisai (TSE:4523): Reassessing Valuation After Recent Share Price Pullback
Eisai (TSE:4523) has slipped over the past month, leaving some investors wondering whether the recent pullback reflects fundamentals or just sentiment. With earnings still growing, the current share p...
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress
We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, ...
China's new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?
Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as "historic" and "the beginning of the end" for the memory-robbing disease af...
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innova...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
